These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25605515)

  • 1. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence.
    Yoo C; Ryu MH; Park YS; Yoo MW; Park SR; Ryoo BY; Jang SJ; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2015 Sep; 22(9):2940-7. PubMed ID: 25605515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnitude of serosal changes predicts peritoneal recurrence of gastric cancer.
    Bando E; Kawamura T; Kinoshita K; Takahashi S; Maeda A; Osada S; Tsubosa Y; Yamaguchi S; Uesaka K; Yonemura Y
    J Am Coll Surg; 2003 Aug; 197(2):212-22. PubMed ID: 12892799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of a risk score for recurrence in patients with curatively resected gastric cancer.
    Ichikura T; Fujino K; Ikawa H; Tomimatsu S; Uefuji K; Tamakuma S
    Surg Today; 1993; 23(9):759-64. PubMed ID: 8219607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery.
    Sun Z; Xu YY; Wang ZN; Zhu Z; Zhang H; Huang BJ; Xu Y; Chen JQ; Xu HM
    Ann Surg Oncol; 2011 Apr; 18(4):1068-80. PubMed ID: 21293933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extent of Serosal Changes Predicts Peritoneal Recurrence and Poor Prognosis After Curative Surgery for Gastric Cancer.
    Kang Y; Li S; Ge Q; Liu X; Yang Z; Xue Y; Wang F
    Medicine (Baltimore); 2015 Oct; 94(42):e1750. PubMed ID: 26496292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis.
    Saito H; Kihara K; Kuroda H; Matsunaga T; Tatebe S; Ikeguchi M
    J Surg Oncol; 2011 Oct; 104(5):534-7. PubMed ID: 21618248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative.
    Squires MH; Kooby DA; Poultsides GA; Pawlik TM; Weber SM; Schmidt CR; Votanopoulos KI; Fields RC; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Levine EA; Jin LX; Cho CS; Bloomston M; Winslow ER; Russell MC; Cardona K; Staley CA; Maithel SK
    Ann Surg Oncol; 2015 Apr; 22(4):1243-51. PubMed ID: 25316491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
    Piessen G; Messager M; Leteurtre E; Jean-Pierre T; Mariette C
    Ann Surg; 2009 Dec; 250(6):878-87. PubMed ID: 19855261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Borrmann's macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis.
    Noda S; Yashiro M; Toyokawa T; Morimoto J; Shinto O; Muguruma K; Sawada T; Hirakawa K
    Ann Surg Oncol; 2011 Dec; 18(13):3718-25. PubMed ID: 21573834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Histologic Type in Curatively Resected Stage IV Colorectal Cancer: A Japanese Multicenter Retrospective Study.
    Shibata J; Kawai K; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Nozawa H; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Sugihara K; Watanabe T
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S621-9. PubMed ID: 26350364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
    Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma.
    Postlewait LM; Squires MH; Kooby DA; Poultsides GA; Weber SM; Bloomston M; Fields RC; Pawlik TM; Votanopoulos KI; Schmidt CR; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Swords D; Jin LX; Cho CS; Winslow ER; Cardona K; Staley CA; Maithel SK
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S832-9. PubMed ID: 26156656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma in the middle third of the stomach--an evaluation for the prognostic significance of clinicopathological features.
    Sheen-Chen SM; Chou CW; Chen MC; Chen FC; Chen YS; Chen JJ
    Hepatogastroenterology; 1997; 44(17):1488-94. PubMed ID: 9356878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma.
    Moon JH; Fujiwara Y; Nakamura Y; Okada K; Hanada H; Sakakura C; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    J Surg Oncol; 2012 Feb; 105(2):189-94. PubMed ID: 21780125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?
    Mariette C; Bruyère E; Messager M; Pichot-Delahaye V; Paye F; Dumont F; Brachet D; Piessen G;
    Ann Surg Oncol; 2013 Apr; 20(4):1240-9. PubMed ID: 23064779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study.
    Zhu ZG; Tang R; Yan M; Chen J; Yang QM; Li C; Yao XX; Zhang J; Yin HR; Lin YZ
    Dig Surg; 2006; 23(1-2):93-102. PubMed ID: 16763374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a risk-scoring system to evaluate the serosal invasion for macroscopic serosal invasion positive gastric cancer patients.
    Wang PL; Huang JY; Zhu Z; Gong BC; Huang HW; Duan SJ; Xu HM; Liu FN
    Eur J Surg Oncol; 2018 May; 44(5):600-606. PubMed ID: 29454557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.